共 27 条
A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples
被引:48
|作者:
Zwart, Wilbert
[1
,5
]
Koornstra, Rutger
[1
]
Wesseling, Jelle
[1
,2
]
Rutgers, Emiel
[3
]
Linn, Sabine
[1
,4
]
Carroll, Jason S.
[5
,6
]
机构:
[1] Netherlands Canc Inst, Dept Mol Pathol, Amsterdam, Netherlands
[2] Netherlands Canc Inst, Dept Pathol, NL-1066 CX Amsterdam, Netherlands
[3] Netherlands Canc Inst, Dept Surg Oncol, Amsterdam, Netherlands
[4] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
[5] Canc Res UK, Cambridge Res Inst, Li Ka Shing Ctr, Cambridge CB2 0RE, England
[6] Univ Cambridge, Dept Oncol, Cambridge CB2 OXY, England
来源:
基金:
欧洲研究理事会;
关键词:
TAMOXIFEN RESISTANCE;
LIMITED NUMBERS;
ALPHA;
BINDING;
CELLS;
D O I:
10.1186/1471-2164-14-232
中图分类号:
Q81 [生物工程学(生物技术)];
Q93 [微生物学];
学科分类号:
071005 ;
0836 ;
090102 ;
100705 ;
摘要:
Background: The Estrogen Receptor alpha (ER alpha) is the key transcriptional regulator in luminal breast cancer and is therefore the main target for adjuvant treatment of this subtype. Luminal gene signatures are dictated by the transcriptional capacities of ER alpha, which are a direct consequence of the receptors binding preference at specific sites on the chromatin. The identification of ER alpha binding signatures on a genome-wide level has greatly enhanced our understanding of Estrogen Receptor biology in cell lines and tumours, but the technique has its limitations with respect to its applicability in limited amounts of tumour tissue. Results: Here, we present a refinement of the ChIP-seq procedures to enable transcription factor mapping on limited amounts of tissue culture cells as well as from a limited amount of tumor tissue derived from core needle biopsies. Our approach uses a carrier that can be removed prior to DNA amplification and sequencing. Conclusion: We illustrate the applicability of this refined technology by mapping the ER alpha genome-wide chromatin binding landscape in core needle biopsy material from primary breast tumours. With this, our refined technology permits for a high-resolution transcription factor mapping even from clinical samples.
引用
收藏
页数:7
相关论文